NEW ORLEANS, LA – Wilkinson Walsh + Eskovitz won the second bellwether trial on June 12, 2017 in the multi-district litigation over the blood thinner Xarelto. Beth Wilkinson, a founding partner of Wilkinson Walsh + Eskovitz, led the defense to victory on behalf of Bayer and Janssen in the second of four bellwether trials in the MDL. The complete defense verdict came just two hours after closing arguments.
This latest victory comes just six weeks after Wilkinson obtained a complete defense verdict in the first bellwether trial in the litigation. The lawsuit alleged that Bayer, and Johnson & Johnson subsidiary Janssen Pharmaceuticals, were liable for claims that the Xarelto label did not adequately instruct doctors on how to minimize the risk of bleeding associated with the anticoagulant Xarelto. In this trial, the plaintiff passed away due to a brain bleed.
Wilkinson Walsh + Eskovitz represented Bayer, with Beth Wilkinson serving as lead trial counsel. David Dukes of Nelson Mullins Riley & Scarborough and James Irwin of Irwin Fritchie Urquhart & Moore also served as trial counsel for Bayer and Janssen, respectively.
The case is In Re: Xarelto (Rivaroxaban) Products Liability Litigation, case number 2:14-md-02592, in the U.S. District Court for the Eastern District of Louisiana.
Press Contact: firstname.lastname@example.org